Delivery Order SPE2DR25D1202-SPE2DR26F71NT
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $30,449.94 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injectors on October 21, 2025, with an ultimate completion date of October 22, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and is being performed at the contractor's facility in Conshohocken, Pennsylvania. Zepbound is a tirzepatide-based medication indicated for weight management...
- The Defense Logistics Agency awarded a $1,906.45 delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 mL pen injectors on August 18, 2025. This non-competitive delivery order represents a firm fixed price transaction with a performance completion date of August 19, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $26,657.11 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pen injections on August 20, 2025, with an ultimate completion date of August 21, 2025. This competitively awarded, non-set-aside firm fixed price delivery order is being performed at the contractor's facility in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a diabetes and weight management medication, consistent with AmerisourceBergen's...
- The Defense Logistics Agency awarded a $1,525.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 mL pen injectors on September 3, 2025, with completion expected by September 4, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. The order will be...
- The Defense Logistics Agency awarded a delivery order valued at $8,624.79 to AmerisourceBergen Drug Corp for the supply of Zepbound 15 mg/0.5 mL pens on August 13, 2025, with an ultimate completion date of August 14, 2025. This competitive, firm fixed-price delivery order was issued without a set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a GLP-1 receptor agonist medication used in diabetes and weight management...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $233,777.40 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pens on August 28, 2025, with an ultimate completion date of August 29, 2025. This competitively awarded, firm fixed-price delivery order was issued without set-aside designations and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a GLP-1 receptor agonist medication used in diabetes and...
- The Defense Logistics Agency awarded a delivery order valued at $8,088.02 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 ml pen injections on July 15, 2025, with completion scheduled for July 16, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a pharmaceutical product used in diabetes and weight management...
- The Defense Logistics Agency awarded a delivery order valued at $2,669.05 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pens on August 14, 2025, with an ultimate completion date of August 15, 2025. This firm fixed-price delivery order, issued without a set-aside designation, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a prescription medication used in diabetes and weight management treatment, and...
- The Defense Logistics Agency awarded a $2,045.91 delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injectors. This competitively awarded, non-set-aside contract is structured as a firm fixed price delivery order with an ultimate completion date of August 11, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Zepbound is a diabetes and weight management medication, reflecting...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,621.24 for Zepbound 5 mg/0.5 mL pens on August 4, 2025, with completion scheduled for August 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a GLP-1 receptor agonist indicated for weight management, representing the...
- SPE2DR25D1202Indefinite Delivery Contract
- SPE2DR25D1202-SPE2DR26F71NTDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $26,102.91 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injectors on October 22, 2025, with an ultimate completion date of October 23, 2025. This competitively awarded, firm fixed-price delivery order was issued without a set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Zepbound (tirzepatide) is a GLP-1 receptor agonist medication used in diabetes and weight management treatment. This delivery order is issued under AmerisourceBergen Drug Corp's prime Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen Drug Corp supplies a comprehensive range of pharmaceutical products and medical supplies to support military healthcare systems and the Defense Health Agency. The company's substantial IDC with the DLA demonstrates its capability to fulfill diverse federal medical supply requirements across multiple therapeutic domains on a global scale.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $26.1k | 10/22/25 |